



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

Medicago to present at the World Health Organization's Third Meeting on Influenza Vaccines

Quebec City, Quebec, November 30, 2007 — Medicago Inc. (TSX-V: MDG) (the "Company"), a developer and manufacturer of protein-based vaccines using a proprietary transient expression system, today announced that it has been invited to present at the World Health Organization's Third Meeting on Influenza Vaccines that induce Broad Spectrum and Long-Lasting Immune Response. Dr. Louis Vezina, Chief Scientist of Medicago will be presenting the Company's preclinical results of a vaccine candidate for H5N1 Avian Influenza generated from plant-made Virus-Like Particles ("VLP").

The meeting will be held in Geneva, Switzerland on December 3 and December 4, 2007 and will be attended by leading scientists in the development of influenza vaccines. The objective of the meeting will be to review new technologies for the development of influenza vaccines, focusing on solutions that induce a broad spectrum and long-lasting immune responses and that provide cross-protection against different influenza viruses.

"World leading experts in vaccine development have been invited to this WHO conference, providing us with an excellent opportunity to increase awareness for the capabilities of our proprietary vaccine development and manufacturing technologies," said Dr. Vezina. "We look forward to discussing recent preclinical results from our lead VLP vaccine, which has demonstrated high levels of potency against the lethal Indonesia strain of the H5N1 Avian Influenza virus, and to presenting our plant-based technology, which significantly increases vaccine manufacturing capacity."

A summary of the meeting and presentations will be published in the coming months on the World Health Organization's website at www.who.int.

About Medicago Inc.

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicargo.com

Forward Looking Statements

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

Contact Information

Medicago Inc.

Andy Sheldon
President and CEO
(418) 658-9393

The Equicom Group Inc.

Arianna Vanin
Investor Relations
(514) 844-4680
avanin@equicomgroup.com